BioWorld

July 2, 2009

No Buyout, but Acorda Banks $110M in Fampridine-SR Deal

It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today) Read More

Myriad's Lowered Guidance Casts Pall over Spin-off Debut

Risk Genes for Schizophrenia Aplenty; Bipolar Shares Some

Biotech Survival Game Prompts CombinatoRx, Neuromed Merger

Holiday Notice

Awaiting FDA Action on Zevalin, Spectrum Seeks to Raise $21M

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...